Novel vitamin D analog for kidney cancer

用于肾癌的新型维生素 D 类似物

基本信息

  • 批准号:
    7647277
  • 负责人:
  • 金额:
    $ 21.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Kidney cancer comprises approximately 3% of all adult malignancies, and account for over 30,000 cases and 12,000 deaths per year. Unfortunately, efficient intervention of this deadly disease is currently lacking, and effective therapy for this deadly disease is urgently needed. Numerous epidemiological studies have strongly demonstrated the importance of dietary vitamin D in preventing various cancers. In addition, therapeutic potential of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active metabolite of vitamin D and its analogs in cancer is well-documented. However, inherent calcemic toxicity of this hormone, particularly at therapeutic doses, has prevented its general use as an anticancer agent, opening the door for the development of vitamin D analogs with potent antiproliferative activity with reduced systemic toxicity. Recently we developed a novel derivative of 1,25(OH)2D3 [11,25- dihydroxyvitamin D3-3-bromoacetate, 1,25(OH)2D3-3-BE] that covalently attaches 1,25(OH)2D3 inside the ligand-binding pocket of VDR. We demonstrated that 1,25(OH)2D3-3-BE strongly inhibits the growth of several human cancer cells, including a set of kidney cancer cells. We also demonstrated that 1,25(OH)2D3-3-BE reduces hormone-insensitive prostate tumor at 0.1-0.5 5g/kg dose level in a mouse xenograft model without significant toxicity. Collectively, these results demonstrate potential therapeutic utility of this compound in kidney cancer. The goal of this R21 proposal is to appraise the potential therapeutic value of 1,25(OH)2D3-3-BE in kidney cancer, and evaluate the molecular mechanism of this novel VDR-cross-linking derivative of 1,25(OH)2D3. These goals will be met by two specific aims: Specific Aim 1: Determine the efficacy of 1,25(OH)2D3-3-BE on human renal cell carcinoma in a mouse xenograft model; and Specific Aim 2: Evaluate the molecular mechanism of growth-inhibition and apoptosis by 1,25(OH)2D3-3-BE in kidney cancer cells. Successful completion of this pilot project will be crucial for the development of 1,25(OH)2D3-3-BE and similar VDR-alkylating analogs of vitamin D hormone for kidney cancer. PUBLIC HEALTH RELEVANCE: Inherent calcemic toxicity of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active metabolite of vitamin D has prevented its general use as an anticancer agent. Recently we developed a novel derivative of 1,25(OH)2D3 that strongly inhibits the growth of several human kidney cancer cells, and induces programmed cell death in these cells. The goal of this project is to evaluate the therapeutic potential of this compound in kidney cancer.
描述(申请人提供):肾癌约占所有成人恶性肿瘤的3%,每年造成30,000多例病例和12,000人死亡。不幸的是,目前缺乏对这种致命疾病的有效干预,迫切需要对这种致命疾病进行有效的治疗。大量的流行病学研究有力地证明了饮食中维生素D在预防各种癌症中的重要性。此外,维生素D及其类似物的生物活性代谢物1,25-二羟基维生素D3(1,25(OH)2D3)在癌症中的治疗潜力也得到了很好的证明。然而,这种激素固有的钙化毒性,特别是在治疗剂量下,阻碍了它作为抗癌药物的普遍使用,为开发具有强大的抗增殖活性并降低全身毒性的维生素D类似物打开了大门。最近我们开发了一种新的1,25(OH)2D3[11,25-二羟基维生素D3-3-溴乙酸酯,1,25(OH)2D3-3-Be]的衍生物,它共价连接到VDR的配体结合袋中。我们证明了1,25(OH)2D3-3-Be对几种人类癌细胞的生长有强烈的抑制作用,其中包括一组肾癌细胞。我们还证明,在小鼠异种移植模型中,1,25(OH)2D3-3-Be在0.1-0.5 5g/kg剂量水平下可以减少激素不敏感的前列腺癌,而没有明显的毒性。总而言之,这些结果证明了这种化合物对肾癌的潜在治疗作用。本R21建议的目的是评价1,25(OH)2D3-3-BE在肾癌中的潜在治疗价值,并评价这种新型VDR-1,25(OH)2D3的交联物的分子机制。这些目标将通过两个特定目标来实现:特定目标1:确定1,25(OH)2D3-3-Be在小鼠异种移植模型中对人肾癌的疗效;以及特定目标2:评价1,25(OH)2D3-3-Be抑制肾癌细胞生长和诱导细胞凋亡的分子机制。这一试点项目的成功完成将对开发治疗肾癌的1,25(OH)2D3-3-BE和类似的维生素D激素的VDR烷基化类似物至关重要。与公共卫生相关:维生素D的生物活性代谢物1,25-二羟基维生素D3(1,25(OH)2D3)固有的钙化毒性阻碍了其作为抗癌剂的广泛使用。最近我们开发了一种新的1,25(OH)2D3的衍生物,它能强烈抑制几种人肾癌细胞的生长,并诱导这些细胞的程序性死亡。该项目的目标是评估这种化合物在肾癌中的治疗潜力。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.
Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells.
1,25-二羟基维生素 D3-3-溴乙酸单独或与 5-氨基-咪唑-4-甲酰胺-1-β-4-呋喃核苷联合使用对胰腺癌细胞的抗生长作用。
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Persons,KellyS;Eddy,VikramJ;Chadid,Susan;Deoliveira,Rosangela;Saha,AsishK;Ray,Rahul
  • 通讯作者:
    Ray,Rahul
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAHUL RAY其他文献

RAHUL RAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAHUL RAY', 18)}}的其他基金

Novel vitamin D analog for kidney cancer
用于肾癌的新型维生素 D 类似物
  • 批准号:
    7471169
  • 财政年份:
    2008
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    6033064
  • 财政年份:
    1999
  • 资助金额:
    $ 21.94万
  • 项目类别:
NON-RADIOACTIVE METHOD FOR 25-OH-D & 1,25 (OH)2D IN BLO
25-OH-D 的非放射性方法
  • 批准号:
    2536578
  • 财政年份:
    1997
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2328525
  • 财政年份:
    1996
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2147002
  • 财政年份:
    1996
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2147003
  • 财政年份:
    1994
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2147000
  • 财政年份:
    1994
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2624498
  • 财政年份:
    1994
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2146999
  • 财政年份:
    1994
  • 资助金额:
    $ 21.94万
  • 项目类别:
MOLECULAR PROBING OF VITAMIN D RECEPTOR
维生素 D 受体的分子探测
  • 批准号:
    2855303
  • 财政年份:
    1994
  • 资助金额:
    $ 21.94万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了